source
- Roche partners with China's Defand Therapeutics to discover molecular glue medicinesRoche announced a collaboration with Chinese biotech Defand Therapeutics aimed at discovering new molecular glue medicines for oncology and immune‑mediated diseases. Unlike typical licensing deals…
- CMS proposes changes to curb 340B drug discount program’s costly subsidies to safety-net hospitalsCasey B. Mulligan, chief economist and chief regulatory officer at HHS, wrote an opinion piece outlining a major flaw in the 340B drug discount program. The program, created in 1992, gives steep di…